L ong-QT syndrome (LQTS), an inherited channelopathy, is a common cause of arrhythmic death in infants, children, and young adults. Although many LQTS genes have been identified, most (≈75%) of LQTS mutations are found in KCNQ1, KCNH2, or SCN5A. In most cases, treatment for LQTS is successful and modifies the risk of life-threatening arrhythmias; thus, making the correct diagnosis is important. The diagnosis of LQTS is made by the measurement of a prolonged QT interval on the standard ECG; family history or characteristic arrhythmia features strengthen the diagnosis, and genetic testing confirms the diagnosis.
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Before birth, however, LQTS is difficult to diagnose because fetal echocardiography, the stalwart in the diagnosis of fetal arrhythmias, cannot measure the QT interval or detect T-wave alternans, and fetal ECG is not feasible. Although fetal magnetocardiography has successfully recorded fetal ECG and identified fetal LQTS, 1 it is available at only a few centers worldwide. Recent studies have identified torsades de pointes (TdP) and second-degree AV block as signature fetal LQTS arrhythmias 1,2 ; these arrhythmias are easily recognized as abnormal but occur in only ≈25% of fetuses with LQTS. The arrhythmia most commonly associated with fetal LQTS is sinus bradycardia. Unfortunately, fetuses with sinus bradycardia often escape recognition because their heart rate and rhythm are not appreciated to be abnormal since the obstetric definition of sinus bradycardia is limited to a fetal heart rate (FHR) of ≤110 beats per minute at every gestational age (GA). 3 This GA-independent definition of fetal bradycardia has been difficult to challenge, despite the known inverse relationship between FHR and GA in normal fetuses 4 and a previous study of in which only 15% of LQTS FHRs were ≤110 beats per minute. 2 Why is it important to suspect the diagnosis of LQTS before birth? One reason is to decrease prenatal morbidity.
Fetuses with LQTS are often delivered prematurely because the LQTS rhythm phenotype of sinus bradycardia or ventricular bradycardia due to second-degree AVB is misinterpreted as fetal distress. 5 Alternatively, the treating physician may be unaware even the hydropic fetus with ventricular tachycardia can be successfully treated in utero. 6 The LQTS fetus may be at increased risk of ventricular tachycardia if low maternal magnesium levels remain untreated or the mother is treated with QT prolonging medications common in obstetric practice such as oxytocin or ondansetron. Other important reasons to suspect a prenatal diagnosis of LQTS are the genetic autopsy findings in unexplained fetal demise and sudden infant death victim: genes associated with ion channel dysfunction or de novo channelopathy gene mutations have been found in 8.8% of the former and ≈10% of the latter. 7, 8 Finally, if LQTS is confirmed after birth in a fetal proband, cascade screening can identify affected but unsuspecting family members. 2 Dr Winbo et al [9] [10] [11] [12] [13] have published extensively on the genotype and postnatal phenotype from Swedish populations with 2 founder KCNQ1 mutations. The 2 KCNQ1 mutations, R518X and Y111C, are thought to be loss-of-function mutations . The annual incidences of cardiac arrhythmia events for postnatal subjects heterozygous for R518X and Y111C are only 0.04% and 0.05%, 9 which is much lower than in other heterozygous nonsense mutations of KCNQ1, 14 other KCNQ1 founder populations, 15 and mutations in other LQTS genes. In this issue of Circulation: Arrhythmia and Electrophysiology, Dr Winbo et al 16 extend our knowledge of the 2 founder populations by defining the prenatal arrhythmia phenotype of the KCNQ1, R518X and Y111C, mutations.
There are 2 important findings in the current study by Winbo et al. 16 First, existing obstetric FHR criteria for sinus bradycardia, that is an FHR of ≤110 beats per minute at any time during gestation, did not define the rhythm phenotype of the KCNQ1 study cohort. On the basis of accepted GA-independent criteria for bradycardia, only 3 of 110 mutationpositive fetuses were suspected to have LQTS. The second important finding is that fetal LQTS demonstrates a mutation dose response for disease severity, including the degree of bradycardia and the likelihood of adverse cardiac events. Thus, not only does FHR differ between mutation carriers and noncarriers, but also FHR correlates inversely with the number of KCNQ1 mutations and the postnatal QTc duration, and directly with mutation functionality. 16 Rather than the accepted definition of bradycardia (FHR≤110 beats per minute), the average third-trimester FHR of KCNQ1 R518X and Y111C mutation carriers was 2 SDs below the mean for mutation-negative fetuses from the same population (ie, ≤133 beats per minute). 16 These higher than expected FHRs for LQTS subjects are similar to the FHRs of LQTS subjects in a previous study, which found that 67% of the heart rates of LQTS fetuses were less than or equal to third percentile for GA, and the cutoff for the third trimester was ≤128 beats per minute. 2 The reason that the FHR cutoff was lower in the study by Mitchell et al 2 may be because the cohort included KCNH2, SCN5A, and uncharacterized LQTS mutations in addition to KCNQ1 mutations.
Only 15% of LQTS FHRs are reported as ≤110 beats per minute, 2 but an FHR of ≤110 beats per minute predicts a severe LQTS phenotype with subjects at high risk for adverse cardiac events. 16 Fetuses with LQTS and sinus bradycardia of ≤110 beats per minute in the third trimester are more likely to have SCN5A R1623Q mutations, uncharacterized or double mutations of KCNQ1, 2,16-18 prolonged pre-and postnatal QTc intervals, 1, 16, 18 and cardiac arrest. In SCN5A R1623Q and some uncharacterized mutations, FHR of ≤110 beats per minute are seen even earlier than the third trimester. 2, 18 Fetuses with double mutations in the Swedish founder KCNQ1 population may also have an FHR of ≤110 earlier in gestation, but this has not yet been evaluated. Whether other mutations in the known LQTS genes may incur a similar high-risk profile based on FHRs of ≤110 beats per minute is unknown and will require further research.
The second important finding in this study by Winbo et al 16 is that even before birth, the LQTS phenotype, including both FHR and the risk for adverse cardiac events, depends on mutation status and functionality. The pre-and postnatal rhythm phenotype of individuals heterozygous for a single KCNQ1, R518X and Y111C, mutations was mild and low risk: the average FHR was 134±8 beats per minute, and 2 of 93 fetuses had nonsustained FHR of >200 beats per minute (presumed ventricular tachycardia). On the contrary, the average thirdtrimester FHR of double-mutation carriers was 111±6 beats per minute, and 1 of 13 fetuses had presumed ventricular tachycardia and 12 adverse cardiac events including appropriate implantable cardioverter defibrillator discharge, TdP, and sudden death were reported after birth. These are important new findings in light of previous publications, suggesting that the fetal/neonatal KCNQ1 phenotype is low risk for serious arrhythmias. 2, 17, 18 Dr Winbo et al 16 raise important questions about the role of FHR in detection of LQTS. 16 Can FHR be used to risk stratify the LQTS fetus, or is it just a marker for LQTS? The answer is both. An FHR of ≤110 beats per minute correlates with a higher risk for perinatal life-threatening cardiac events, and LQTS mutations not commonly seen in adulthood, such as SCN5A R1623Q, uncharacterized mutations, dominant negative single KCNQ1 mutations, and double KCNQ1 mutations. 1, 2, [16] [17] [18] As a marker for LQTS, a mean FHR of ≤133 beats per minute in the third trimester has a high specificity (>97%) but low sensitivity (<50%). 16 It is not known whether FHR at a different points in gestation might increase the sensitivity of FHR for LQTS detection.
How can we use these data in clinical practice? Can we extrapolate the third-trimester LQTS FHR results to the lowrisk population? Do we ask our obstetric and pediatric colleagues to refer newborns with a mean FHR of ≤133 beats per minute during the third trimester for a postnatal ECG, knowing the sensitivity of that FHR in LQTS detection is <50% 16 ?
Or do we evaluate only those newborns with a mean thirdtrimester FHR of ≤110 beats per minute?
Additional data are clearly needed. A reasonable approach would be to build important findings by Winbo et al 16 and not only prospectively evaluate third-trimester FHR in families with a KCNQ1 mutations but also develop an FHR/GA profile in families with KCNH2, SCN5A, and other KCNQ1 mutations. Once defined, the FHR/GA profile for the common LQTS mutations could alert obstetric care providers to the possibility of LQTS and the need for postnatal ECG testing. Incorporating FHR/GA data in neonatal LQTS ascertainment may improve the cost-benefit ratio of neonatal ECG screening to identify those at risk for cardiac arrest. 19, 20 In summary, Winbo et al 16 have made an important contribution to our understanding of the third-trimester FHR and rhythm phenotype of specific KCNQ1 mutations. 16 Until technological advances allow for accurate and readily available fetal ECG recordings, the suspicion of neonatal LQTS rests on critical evaluation of the FHR, and recognizing what is an abnormal FHR. The failure to suspect LQTS before birth misses a critical window of opportunity for anticipatory care and treatment for LQTS subjects of all ages.
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